Advancing Next-Generation Therapies for
Post-Traumatic Stress Disorder
Chiral Biotech Pharma is developing innovative, clinically validated oral treatments for severe mental health conditions—starting with PTSD. Our precisely engineered small-molecule therapies are designed to deliver real-world impact and improve patient outcomes.
Who We Are
We are a clinical-stage biopharmaceutical company creating novel oral therapies for complex psychiatric conditions through rigorous science and modern trial design.
Our Focus
Our first target is PTSD—a widespread, debilitating condition where current treatments often fall short. We aim to deliver optimized therapies that improve symptoms, daily functioning, and quality of life.
Our Approach
Our approach is evidence-driven, built on robust, randomized, double-blind, placebo-controlled clinical trials to ensure scientific rigor. We remain patient-centric, designing oral therapies and practical treatment plans that fit seamlessly into real-world daily life. Through a collaborative network of global investigators and clinical sites, we gather diverse, high-quality data to advance therapies that are both effective and widely applicable.
Leadership & Advisors
Our Leadership & Advisors unite scientific vision and clinical expertise to guide breakthroughs that redefine care for patients living with complex psychiatric conditions.
Chief Clinical Officer (CCO)
Dr. Adrian Keller
Contact Chiral Biotech Pharma
For general information about Chiral Biotech Pharma, our research programs, or partnership opportunities:
info@chiralbiotechpharma.com
+94 77 1234 567
Level 13, 2 Elizabeth St, Melbourne VIC 3000, Australia
Clinical trial enquiries
For enquiries related to the Phase 2 PTSD trial
.c6508b01.svg){kind=small}
trials@chiralbiotechpharma.com
.294c7250.svg){kind=small}
+94 77 1234 567
Who we are
Chiral Biotech Pharma develops next-generation oral therapies for complex psychiatric conditions, starting with PTSD.
Stay up to date
Social Handles
© 2025 Chiral Biotech Pharma. All rights reserved.
